Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

3.480 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 AM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Corvus Pharma Com

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Corvus Pharmaceuticals is Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Corvus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Announces Publication of Preclinical Study Results Demonstrating CPI-444 Antitumor Activity as Monotherapy and in Combination with Anti-PD-1 Therapy in Cancer Immunology, Immuno
Research elucidated novel mechanisms of CPI-444 indicating broad effects on several checkpoints 
From GlobeNewswire News Releases
44 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares jumped 103.9 percent to close at $5.75 on Monday. Xerium Technologies, ... 
Tags Movers From Yesterday CPB ATV
From Benzinga
Top Buys by Directors: Gould's $5M Bet on CRVS
The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company... 
Tags Stocks
From Market News Video
Short Interest Moves 26.5% Lower For CRVS
The most recent short interest data has been released for the 05/31/2018 settlement date, which shows a 314,770 share decrease in total short interest for Corvus Pharmaceuticals Inc (CRVS), to 873,043,... 
Tags Stocks
From Market News Video
Benzinga's Top Upgrades, Downgrades For June 5, 2018
Top Upgrades Craig-Hallum upgraded Teladoc, Inc. (NYSE: TDOC) from Hold to Buy. Teladoc shares rose 2.31 percent to $53.10 ... 
Tags JNCE Downgrades ABEO
From Benzinga
44 Biggest Movers From Yesterday
Gainers American Electric Technologies, Inc (NASDAQ: AETI) shares surged 126.35 percent to close at $1.675 on Monday after ... 
Tags Benzinga EOLS News
From Benzinga
Corvus Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
CRVS Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of Corvus Pharmaceuticals Inc (CRVS) crossed above their 200 day moving average of $11.70, changing hands as high as $12.49 per share. Corvus Pharmaceuticals Inc shares... 
Tags Stocks
From Market News Video
We Did The Math EQWS Can Go To $50
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
Three-arm Trial Will Evaluate CPI-006 as Monotherapy, in Combination with CPI-444 Adenosine Antagonist and in Combination with Pembrolizumab 
From GlobeNewswire News Releases
BRIEF-Adams Street Partners Reports 15.5 Pct Stake In Corvus Pharma
* ADAMS STREET PARTNERS, LLC REPORTS 15.5 PERCENT STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 12, 2018 - SEC FILING?? 
Tags companyNews
From Reuters: Company News
BRIEF-BVF Partners Reports 6.7 Pct Passive Stake In Corvus Pharmaceuticals
* BVF PARTNERS L.P. REPORTS 6.7 PERCENT PASSIVE STAKE IN CORVUS PHARMACEUTICALS INC AS OF MARCH 8, 2018 - SEC FILING?? Source text: (http://bit.ly/2G67UVx) Further company coverage: 
Tags companyNews
From Reuters: Company News
Tuesday 3/13 Insider Buying Report: DLTR, CRVS
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. 
Tags Stocks
From Market News Video
BRIEF-Corvus Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
* CORVUS PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Corvus Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 7,058,824 shares of its common stock at a price to the public of $8.50 per share. 
Tags Pharma/Biotech Healthcare Stocks / Equities
From Blogs - TalkMarkets
45 Stocks Moving In Thursday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 71.2 percent to $14.46 after the company disclosed positive results in ... 
Tags IMRN NTLA SHLO
From Benzinga
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target... 
From GlobeNewswire News Releases
32 Stocks Moving In Thursday's Pre-Market Session
Gainers Express Scripts Holding Company (NASDAQ: ESRX) rose 19.9 percent to $88.00 in pre-market trading. CIGNA Corporation ... 
Tags CKPT Trading Ideas Top Gainers
From Benzinga
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that precisely target... 
From GlobeNewswire News Releases
Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that... 
From GlobeNewswire News Releases
BRIEF-Corvus Pharmaceuticals Qtrly Net Loss Per Share $0.58
* CORVUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE 
Tags companyNews
From Reuters: Company News
Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced... 
From GlobeNewswire News Releases
Look Under The Hood: IWV Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
Company’s Investigational Small Molecule Inhibitor Demonstrates Safety and Activity in Canine Spontaneous T-Cell Lymphoma 
From GlobeNewswire News Releases
48 Biggest Movers From Yesterday
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 72.29 percent to close at $2.86 on Monday. The Israel-based company offers ... 
Tags TRVN CROX YERR
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback